Key result
Women with metabolic syndrome components had significantly higher circulating irisin (P<0.05) and betatrophin (P<0.001), and lower ZAG (P<0.001) and adiponectin (P<0.01) than healthy women.
Why the study?
The study sought to investigate the relationship between circulating ZAG, irisin, betatrophin, and adiponectin concentrations and MetS components, and to evaluate the in vivo effects of blood glucose and insulin on these cytokines.
Are circulating levels of ZAG, irisin, betatrophin, and adiponectin associated with metabolic syndrome components in young women?
Cross-Sectional (n=196)
Are circulating levels of ZAG, irisin, betatrophin, and adiponectin associated with metabolic syndrome components in young women?
Circulating levels of ZAG, irisin, betatrophin, and adiponectin are significantly altered in young women with metabolic syndrome components, suggesting their potential utility as screening biomarkers.
Adipokine differences associate with MetS components in young women; hypothesis-generating for screening biomarkers, needs prospective validation.
BACKGROUND: The purpose of this study was to investigate the relationship between circulating zinc α 2-glycoprotein (ZAG), irisin, betatrophin and adiponectin concentrations and metabolic syndrome (MetS) components and to analyze the effects of blood glucose and insulin on these cytokine concentrations in vivo. METHODS: A total of 196 young women, including 78 healthy women and 118 women with MetS components, were recruited for this cross-sectional study. An oral glucose tolerance test and euglycemic-hyperinsulinemic clamp (EHC) were performed in healthy subjects and women with MetS components. An ELISA kit was used to measure serum ZAG, irisin, betatrophin, and adiponectin levels, and their relationship with the MetS components was analyzed. RESULTS: In women with MetS components, circulating irisin and betatrophin levels were significantly higher than those in the healthy women ((207 (150-248) vs 178 (147-228); P < 0.05) for irisin; (0.51 (0.38-0.63) vs 0.38 (0.23-0.52); P < 0.001) for betatrophin), but circulating ZAG and adiponectin levels were significantly lower (39.8 (26.4-50.4) vs (46.7 (40.6-63.0); P < 0.001) for ZAG; (36.5 (22.0-47.6) vs 41.2 (35.7-54.7); P < 0.01) for adiponectin). FBG, WC, and triglyceride were significantly correlated with the circulating levels of these four cytokines (P < 0.001 or <0.05). All four cytokines were associated with MetS and its components. In response to increasing insulin levels, circulating ZAG concentrations were markedly increased in both healthy subjects and women with MetS components during the EHC. However, serum irisin, betatrophin, and adiponectin levels in both healthy subjects and women with MetS components were significantly reduced compared with baseline. CONCLUSION: Serum ZAG, irisin, betatrophin and adiponectin were associated with MetS and might be biomarkers for screening MetS components.
No takes yet. Share an insight, caveat, or question.
Tan et al. (2020) conducted a cross-sectional in Metabolic syndrome (n=196). Metabolic syndrome components vs. Healthy women was evaluated on Circulating levels of ZAG, irisin, betatrophin, and adiponectin. Women with metabolic syndrome components had significantly higher circulating irisin (P<0.05) and betatrophin (P<0.001), and lower ZAG (P<0.001) and adiponectin (P<0.01) than healthy women.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: